Abstract
Introduction We assessed the usefulness of SARS-CoV-2 RT-PCR cycle thresholds (Ct) values trends produced by the LHUB-ULB (a consolidated microbiology laboratory located in Brussels, Belgium) for monitoring the epidemic’s dynamics at local and national levels and for improving forecasting models.
Methods SARS-CoV-2 RT-PCR Ct values produced from April 1, 2020, to May 15, 2021, were compared with national COVID-19 confirmed cases notifications according to their geographical and time distribution. These Ct values were evaluated against both a phase diagram predicting the number of COVID-19 patients requiring intensive care and an age-structured model estimating COVID-19 prevalence in Belgium.
Results Over 155,811 RT-PCR performed, 12,799 were positive and 7,910 Ct values were available for analysis. The 14-day median Ct values were negatively correlated with the 14-day mean daily positive tests with a lag of 17 days. In addition, the 14-day mean daily positive tests in LHUB-ULB were strongly correlated with the 14-day mean confirmed cases in the Brussels-Capital and in Belgium with coinciding start, peak and end of the different waves of the epidemic. Ct values decreased concurrently with the forecasted phase-shifts of the diagram. Similarly, the evolution of 14-day median Ct values was negatively correlated with daily estimated prevalence for all age-classes.
Conclusion We provide preliminary evidence that trends of Ct values can help to both follow and predict the epidemic’s trajectory at local and national levels, underlining that consolidated microbiology laboratories can act as epidemic sensors as they gather data that are representative of the geographical area they serve.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no financial support for this research. SD is supported by the Fonds National de la Recherche Scientifique (FNRS, Belgium). NF, CF and NH acknowledge support from the European Union's Horizon 2020 research and innovation program (NF, NH: grant number 682540 - TransMID project; CF, NH: grant number 101003688 - EpiPose project).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics comittee of Saint-Pierre University Hospital (Brussels, Belgium)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The complete de-identified data set will be available upon request to Nicolas.yin@lhub-ulb.be for researchers whose proposed use of the data has been approved, for any purpose. If needed, requests will require the ethics committee approval of the Saint-Pierre University Hospital (Brussels, Belgium). Anonymized data are fully available on reasonable request from the corresponding author after approval by the hospital ethics committee. Data Availability Statement. R script and related files needed to run the analyses and generate Figures 1, 3, 4 and 5 presented in our study are all available at https://github.com/sdellicour/Ct_measures_LHUB.
